Skip to content

CG Oncology (CGON) stock

Common stock · Nasdaq

Know the moment the smart money buys or sells CG Oncology.

See who owns CG Oncology, what its own executives are doing with their shares and what social media is saying, with an alert the moment any of it changes.

  • Every stock, fund, option and crypto you own, in one place.
  • News, fundamentals and technicals, explained by AI in plain English.
  • Congress, top fund managers, insiders, analysts and social media signals, with an alert the moment they move.

No credit card30 days of Pro free

Instaport’s take on CG Oncology

Fair value

Members see our fair value estimate

Our model’s fair value is , from today’s price.

Quant score
/ 10
  • Momentum
  • Revisions
  • Profitability
  • Growth
  • Valuation
AI summary

CG Oncology is up 95% over the past year, ahead of the S&P 500’s 7% gain.

See the full fair value, quant grades and AI summary, for CG Oncology and every stock you own.
Sign up free

No credit card30 days of Pro free

Never be the last to know

When a top fund, Congress or CG Oncology’s own executives buy or sell, you hear about it the day it goes public, not weeks later in the news.

Hours and days of research in minutes

Congress, top fund managers, insiders, analysts and social media, on every stock you own, in one glance. No more checking five websites.

Invest with confidence

AI explains what each move means for your portfolio in plain English, so you know what you own and why.

CG Oncology at a glance

Price$79.48Nov 20 close
Day change−2.95%
52-week range$37.01 – $93.95
Market cap$7.10B
P/E-28.8
Next earnings—
Next-quarter EPS estimate−$0.6810 analysts
Short interest10.32%of shares outstanding
Social chatter—
Past year: CG Oncology +95% vs S&P 500 +7%CG OncologyS&P 500

Who owns CG Oncology

Top fund managers

Fund · manager% of their portfolioValue
Winton GroupDavid Harding0.09%$2.42M
Woodline PartnersMichael Rockefeller0.09%$29.43M
Fisher Asset ManagementKen Fisher0.01%$33.81M

CG Oncology’s executives: 17 sales and 4 open-market buys in their last 36 reported trades.

8 top funds and 0 members of Congress own CG Oncology. See them all free →

CG Oncology (CGON): funds that hold it

#Fund% of fund
1SBIOALPS Medical Breakthroughs ETF3.41%
2CANCTema Oncology ETF2.76%
3XBIState Street SPDR S&P Biotech ETF1.20%
4WDNAWisdomTree BioRevolution Fund0.90%
5LABUDirexion Daily S&P Biotech Bull 3X ETF0.88%
6BBCVirtus Biotech Clinical Trials ETF0.80%
7FNYFirst Trust Mid Cap Growth AlphaDEX Fund0.64%
8JDOCJPMorgan Healthcare Leaders ETF0.62%
9TMEDT. Rowe Price Health Care ETF0.62%
10ACSGAmerican Century Small Cap Growth Insights ETF0.48%

Questions about CG Oncology stock

Which top fund managers own CG Oncology stock?

David Harding’s Winton Group holds CGON, about 0% of its portfolio (roughly $2.4M) as of its latest filing. Michael Rockefeller’s Woodline Partners and Ken Fisher’s Fisher Asset Management are also large holders.

Are CG Oncology insiders buying or selling?

Mostly selling. CG Oncology insiders made 17 sales and 4 open-market buys in their last 36 reported transactions.

Power your portfolio with AI.

Know what’s moving your investments in minutes, so you can invest better.

Sign up free

No credit card30 days of Pro free

Information and analytics, not investment advice.